Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bolt Biotherapeutics (BOLT) Retained Earnings (2019 - 2025)

Historic Retained Earnings for Bolt Biotherapeutics (BOLT) over the last 7 years, with Q3 2025 value amounting to -$454.1 million.

  • Bolt Biotherapeutics' Retained Earnings fell 1036.4% to -$454.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$454.1 million, marking a year-over-year decrease of 1036.4%. This contributed to the annual value of -$427.4 million for FY2024, which is 1732.65% down from last year.
  • Bolt Biotherapeutics' Retained Earnings amounted to -$454.1 million in Q3 2025, which was down 1036.4% from -$447.0 million recorded in Q2 2025.
  • Bolt Biotherapeutics' 5-year Retained Earnings high stood at -$132.9 million for Q1 2021, and its period low was -$454.1 million during Q3 2025.
  • Moreover, its 5-year median value for Retained Earnings was -$330.1 million (2023), whereas its average is -$317.5 million.
  • Its Retained Earnings has fluctuated over the past 5 years, first tumbled by 9095.19% in 2021, then tumbled by 1036.4% in 2025.
  • Quarter analysis of 5 years shows Bolt Biotherapeutics' Retained Earnings stood at -$207.0 million in 2021, then tumbled by 42.56% to -$295.1 million in 2022, then decreased by 23.45% to -$364.3 million in 2023, then fell by 17.33% to -$427.4 million in 2024, then dropped by 6.26% to -$454.1 million in 2025.
  • Its Retained Earnings was -$454.1 million in Q3 2025, compared to -$447.0 million in Q2 2025 and -$438.4 million in Q1 2025.